Skip to main content
SpringerLink
Log in

A Recently Developed Typhoid Vi Polysaccharide Vaccine

Rationale and Clinical Profile

  • Introduction
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Use of trade names is for identification purposes only and does not imply endorsement.

References

  1. World Health Organization. The Children’s Vaccine Initiative (CVI) and WHO’s Global Programme for Vaccines and Immunization (GPV). Recommendations from the Scientific Advisory Group of Experts (SAGE). Pt 1. Wkly Epidemiol Rec 1998; 73(37): 281–8

    Google Scholar 

  2. Levine MM, Black RE, Ferreccio C, et al. Interventions to control endemic typhoid fever: field studies in Santiago, Chile. In: Association PAH, editors. Control and eradication of infectious diseases. International Organization Co-publication. Series. No. 1, 1985: 37-53

  3. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ 1994; 72(6): 957–71

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Ivanoff B. Typhoid fever: global situation and WHO recommendations. Southeast Asian J Trop Med Public Health 1995; 26: 1–6

    Google Scholar 

  5. The World Health Report 1996 — fighting disease, fostering development. World Health Forum 1997; 18 (1): 1-8

  6. Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1997; 24: S106–9

    Article  Google Scholar 

  7. Patnaik KC, Kapoor PN. A note on incidence of typhoid in Delhi. Indian J Med Res 1967; 55: 228–39

    Google Scholar 

  8. UK Department of Health. Typhoid. In: Salisbury DM, Begg NT, editors. Immunisation against infectious disease. Bicentenary edition. Lndon: Edward Jenner, 1996: 243–9

    Google Scholar 

  9. Steffen R. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations. Vaccine 1993; 11: 518–20

    Article  CAS  Google Scholar 

  10. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158: 633–8

    Article  CAS  Google Scholar 

  11. Jones ME, Welsby P. Typhoid fever: an overview. Travel Med Pract 1999; 1: 18–20

    Google Scholar 

  12. Centers for Disease Control and Prevention. Preventing typhoid fever: a guide for travelers. Revised Nov 1, 2000. Available from: URL: http://www.cdc.gov/travel/typhoid.htm [Accessed 2001 Sep 18]

  13. Kozicki M, Steffen R, Schar M. ’Boil it, cook it, peel it, or forget it’: does this rule prevent travellers’ diarrhoea? Int J Epidemiol 1985; 14: 169–72

    Article  CAS  Google Scholar 

  14. Gupta A. Multidrug-resistant typhoid fever in children: epidemiology and therapeutic approach. Pediatr Infect Dis J 1994; 13: 134–40

    Article  CAS  Google Scholar 

  15. Tarr PE, Kuppens L, Jones TC, et al. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999; 61: 163–70

    Article  CAS  Google Scholar 

  16. World Health Organization. International travel and health: vaccination requirements and health advice. Situation as on Jan 1, 2001. Available from: URL: http://www.who.int/ith/english/

  17. Engels EA, Falagas ME, Lau J, et al. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 316: 110–6

    Article  CAS  Google Scholar 

  18. Cryz Jr SJ. Patient compliance in the use of Vivotif Berna® vaccine, typhoid vaccine, live oral Ty21a. J Travel Med 1998; 5: 14–7

    Article  Google Scholar 

  19. Wiedermann G. Patient compliance in the use of Vivotif Berna® vaccine, typhoid vaccine, live oral Ty21a. J Travel Med 1998; 5: 1–2

    Article  CAS  Google Scholar 

  20. Ambrosch F, Hirschl A, Kollaritsch H, et al. Untersuchungen zur Kompatibilität des neuen Malariamittels Mefloquin mit der oralen Typhus-Lebendimfung. Mitt Osterr Ges Tropenmed Parasitol 1987; 9: 167–72

    Google Scholar 

  21. Cobelens FG, Kooij S, Warris-Versteegen A, et al. Typhoid fever in group travelers: opportunity for studying vaccine efficacy. J Travel Med 2000; 7: 19–24

    Article  CAS  Google Scholar 

  22. Jelinek T, Nothdurft H-D, von Sonnenburg F, et al. Risk factors for typhoid in travelers. J Travel Med 1996; 3: 200–3

    Article  CAS  Google Scholar 

  23. Schwartz E, Shlim DR, Eaton M, et al. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med 1990; 150: 349–51

    Article  CAS  Google Scholar 

  24. Hirschel B, Wuthrich R, Somaini B, et al. Inefficacy of the commercial live oral Ty21a vaccine in the prevention of typhoid fever. Eur J Clin Microbiol 1985; 4: 295–8

    Article  CAS  Google Scholar 

  25. Typhim Vi™ prescribing information. Lyon, France: Avenus Pasteur SA, 1994

  26. Typherix™ summary of product characteristics. Rixensart, Belgium: GlaxoSmithKline Biologicals, 1998

  27. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. New Engl J Med 2001; 344: 1263–9

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF, UK

    Jane N. Zuckerman (Director of the Academic Centre for Travel Medicine & Vaccines and The Royal Free Travel Health Centre, Medical Director of the Royal Free Clinical Trials Centre)

Authors
  1. Jane N. Zuckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jane N. Zuckerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zuckerman, J.N. A Recently Developed Typhoid Vi Polysaccharide Vaccine. BioDrugs 15 (Suppl 1), 1–4 (2001). https://doi.org/10.2165/00063030-200115001-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115001-00001

Keywords

Search

Navigation